Study #2016-0914
A Phase II Trial of Ibrutinib in previously untreated high risk smoldering mantle cell lymphoma (MCL)
MD Anderson Study Status
Not Accepting
Treatment Agent
Ibrutinib
Description
This phase II trial studies how well ibrutinib works in treating participants with untreated high risk smoldering mental cell lymphoma. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Mantle Cell Lymphoma
Study phase:
Phase II
Physician name:
Michael Wang
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-338-0349
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.